Search Results

A Stony Brook University team of researchers led by Gábor Balázsi , PhD, has identified DNA amplification as a major cause of drug resistance in engineered mammalian cell lines and has identified a novel approach to overcome it in those cells as well as in two human cancer cell lines.

Parent Project Muscular Dystrophy announced the expansion of their renowned Certified Duchenne Care Center Program with the certification of Stony Brook Children’s Hospital, in Stony Brook, New York.

Helius Medical Technologies, Inc. today announced the expansion of the registrational program with the addition of Brooks Rehabilitation Hospital (“Brooks Rehabilitation”).

Empress Therapeutics today announced that Virginia Finnerty-Brooks has been appointed Chief Business Officer (CBO).

The Muscular Dystrophy Association announced Brooke Eby will be the keynote speaker at the 2024 MDA Clinical & Scientific Conference, where she will address the world’s leaders in neuromuscular disease research and care.

Solid Biosciences Inc. today announced the appointment of Gabriel Brooks, M.D., as Chief Medical Officer.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that its wholly-owned subsidiary, Applied DNA Clinical Laboratories, LLC (“ADCL”), will provide its COVID-19 surveillance testing program to the Stony Brook University Seawolves men’s and women’s basketball teams

Qosina is pleased to announce that Scott Herskovitz, President and CEO, has joined the Medical Advisory Board (MAB) of the Center of Excellence in Wireless and Information Technology (CEWIT) at Stony Brook University.

Artelo Biosciences, Inc. announced that the National Cancer Institute has awarded Stony Brook University a $4.2 million grant to advance the development of its fatty acid binding protein 5 inhibitor platform.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.